Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on rare disease treatments through cell and exosome-based therapeutics, has scheduled its Q3 2024 financial results release and corporate update for November 13, 2024. The company will host a conference call and webcast at 4:30 p.m. ET following the market close. Investors can access the call via toll-free numbers or through a webcast link, with a replay available on the company's website after the event.
Capricor Therapeutics (NASDAQ: CAPR), un'azienda biotecnologica focalizzata sul trattamento delle malattie rare tramite terapie a base di cellule ed eseosomi, ha programmato il rilascio dei suoi risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per il 13 novembre 2024. L'azienda ospiterà una conference call e una webcast alle 16:30 ET, dopo la chiusura del mercato. Gli investitori possono accedere alla chiamata tramite numeri verdi o attraverso un link per la webcast, con una registrazione disponibile sul sito web della società dopo l'evento.
Capricor Therapeutics (NASDAQ: CAPR), una empresa biotecnológica centrada en tratamientos para enfermedades raras mediante terapias basadas en células y exosomas, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 y una actualización corporativa para el 13 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 p.m. ET después del cierre del mercado. Los inversores pueden acceder a la llamada a través de números gratuitos o mediante un enlace a la transmisión web, con una repetición disponible en el sitio web de la empresa después del evento.
Capricor Therapeutics (NASDAQ: CAPR)는 세포 및 외소포를 기반으로 한 치료법을 통해 희귀 질환 치료에 중점을 둔 생명공학 회사로, 2024년 3분기 재무 결과 발표 및 기업 업데이트를 2024년 11월 13일로 예정하였습니다. 회사는 시장 종료 후 오후 4시 30분(동부 표준시)에 컨퍼런스 콜 및 웹캐스트를 진행합니다. 투자자들은 무료 전화번호 또는 웹캐스트 링크를 통해 통화에 접속할 수 있으며, 이벤트 이후 회사 웹사이트에서 다시 시청할 수 있습니다.
Capricor Therapeutics (NASDAQ: CAPR), une entreprise biopharmaceutique axée sur le traitement des maladies rares par le biais de thérapies basées sur des cellules et des exosomes, a programmé la publication de ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise pour le 13 novembre 2024. L'entreprise tiendra une conférence téléphonique et un webinaire à 16h30 ET, après la fermeture du marché. Les investisseurs peuvent accéder à l'appel via des numéros gratuits ou à travers un lien de webinaire, avec un enregistrement disponible sur le site web de l'entreprise après l'événement.
Capricor Therapeutics (NASDAQ: CAPR), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung seltener Krankheiten mit Zell- und Exosom-basierten Therapeutika konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 und ein Unternehmensupdate für den 13. November 2024 angesetzt. Das Unternehmen wird eine Telefonkonferenz und ein Webcast um 16:30 Uhr ET nach Marktschluss abhalten. Investoren können über gebührenfreie Nummern oder einen Webcast-Link auf den Anruf zugreifen, und eine Wiederholung wird nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Company to Host Conference Call, November 13, 2024 at 4:30 p.m. ET
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13.
| Title: | Capricor Therapeutics Third Quarter 2024 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Wednesday, November 13, 2024 |
| Time: | 4:30 p.m. ET |
| Conference Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 68076 Participants can use guest dial-in numbers above and be answered by an operator or click the Call me™ link for instant telephone access to the event. |
| Webcast: | Webcast Link - Click Here |
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 8, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ
When will Capricor Therapeutics (CAPR) release its Q3 2024 financial results?
What time is Capricor Therapeutics (CAPR) Q3 2024 earnings call?
How can investors access Capricor Therapeutics (CAPR) Q3 2024 earnings call?
